Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer
Crossref DOI link: https://doi.org/10.1007/s00280-017-3313-x
Published Online: 2017-04-27
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ikeda, Masafumi
Takahashi, Hideaki
Kondo, Shunsuke
Lahn, Michael Mauritius Fabio
Ogasawara, Ken
Benhadji, Karim A.
Fujii, Hisaki
Ueno, Hideki
Funding for this research was provided by:
Eli Lilly and Company (US)
License valid from 2017-04-27